I am a clinician researcher dedicated to the care and treatment of patients with lymphoma. I was drawn to this area of oncology because of the immense amount of hope we can offer patients; many types of lymphoma are treated with the intent to cure, and we frequently have a variety of treatment choic...

Certified Specialties

Hematology - American Board of Internal Medicine

Internal Medicine - American Board of Internal Medicine

Medical Oncology - American Board of Internal Medicine

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2020 - 2023

Residency, Internal Medicine, University of Rochester Medical Center. 2017 - 2019

Internship, Internal Medicine, University of Rochester Medical Center. 2016 - 2017

Education

MD | SUNY Upstate Medical University College of Medicine. 2016

Awards

American Society of Hematology Medical Educators Institute. 2023

Segel-Halterman Award for Research in Hematology. 2022

Wilmot Cancer Institute Fellowship Award in Humanism. 2021

Arnold P. Gold Foundation Humanism and Excellence in Teaching Award. 2018

Alpha Omega Alpha Honor Society. 2015

Gold Humanism Honor Society. 2015

Research

Clinical Trials

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma

Lead Researcher: Danielle S Wallace

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously ...

Publications

Journal Articles

How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma.

Wallace DS, Loh KP, Casulo C

Blood.. 2025 January 16145 (3):277-289. Epub 1900 01 01.

Ready, AIM, stop: ibrutinib plus venetoclax in MCL.

Wallace DS, Barr PM

Blood.. 2024 August 22144 (8):800-802. Epub 1900 01 01.

George GV, Aldowitz DG, Jajosky AN, Wallace DS, Burack WR, Friedberg JW, El Hussein S

EJHaem.. 2024 June 5 (3):599-602. Epub 04/24/2024.

ALK-rearranged CD30-positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large-cell lymphoma.

George GV, Wallace DS, Wang Y, Carney J, Elsadawi M, Burack WR, Evans AG, Barr PM, Velez MJ, El Hussein S

Histopathology.. 2024 April 84 (5):900-902. Epub 11/30/2023.

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.

Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM

Blood advances.. 2024 January 238 (2):378-387. Epub 1900 01 01.

Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Wallace DS, Rowland C, Hill BT, Baran AM, Casulo C, Reagan PM, Winter A, Karmali R, Winter JN, Gordon LI, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Ma S, Barr PM

Leukemia & lymphoma.. 2023 September 64 (9):1579-1582. Epub 06/21/2023.

Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW, Barr PM

Blood advances.. 2023 June 137 (11):2496-2503. Epub 1900 01 01.

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.

Moore JE, Bloom PC, Chu CC, Bruno JE, Herne CA, Baran AM, Quataert SA, Mosmann TR, Taylor RP, Wallace DS, Elliott MR, Barr PM, Zent CS

Leukemia research.. 2023 June 129 :107072. Epub 03/29/2023.

A Multicentered Academic Medical Center Experience of a Simulated Root Cause Analysis (RCA) for Hematology/Oncology Fellows.

Wallace D, Cochran D, Duff J, Close J, Murphy M, Baran A, Patel A

Journal of cancer education : the official journal of the American Association for Cancer Education.. 2022 August 37 (4):911-914. Epub 10/14/2020.

Wallace, DS; Reagan PM.

Age is just a number: managing relapsed or refractory diffuse

Early Progressing Follicular Lymphoma.

Wallace D, Casulo C

Current oncology reports.. 2021 November 1923 (12):149. Epub 11/19/2021.

Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.

Wallace D, Reagan PM

Drugs.. 2021 April 81 (6):669-684. Epub 03/30/2021.

Gin Would Be Better.

Wallace D

Journal of palliative medicine.. 2020 August 23 (8):1132. Epub 1900 01 01.

Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).

Meacham PJ, Williams AM, Strawderman M, Baran AM, Archibald WJ, Wallace DS, Tschernia NP, Burack WR, Barr PM, Zent CS

Leukemia & lymphoma.. 2020 July 61 (7):1636-1644. Epub 03/16/2020.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.